Valuation : Profound Medical Corp.

Market Cap 362M 260M 224M 210M 192M 24.84B 363M 2.48B 962M 12.53B 978M 957M 41.51B P/E 2026 *
-8.26x
P/E 2027 * -12.1x
Enterprise Value 362M 260M 224M 210M 192M 24.84B 363M 2.48B 962M 12.53B 978M 957M 41.51B EV / Sales 2026 *
9.99x
EV / Sales 2027 * 6.08x
Free-Float
95.91%
Yield 2026 *
-
Yield 2027 * -
1 day+5.10%
1 week+1.54%
Current month-4.62%
1 month-3.70%
3 months+5.77%
6 months-7.30%
Current year-8.08%
1 week 9.06
Extreme 9.06
10.21
1 month 9.03
Extreme 9.03
11.98
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.61
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
Director of Finance/CFO - 14/08/2026
President 44 07/11/2024
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Buy

Executive/Senior Manager

3,755 0.0103%
14/08/26 Other

Chief Financial Officer

0 0%
14/08/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+5.10%+1.54%+59.16%-7.99% 260M
-0.73%+0.70%+29.46%+15.91% 234B
+0.45%+0.06%+5.39%-17.38% 151B
-0.85%-1.38%-21.61%+22.51% 131B
-2.00%-3.28%-54.90%-11.23% 69.81B
-0.75%+0.96%+12.10%+19.28% 52.33B
-0.88%-2.03%-17.36%-14.75% 50.91B
+2.00%+1.54%+33.71%+32.34% 43.8B
+1.77%+4.05%+42.92%+49.61% 40.69B
+0.02%+3.01%-16.55%+45.36% 34B
Average +0.49%+0.19%+7.23%+13.37% 80.84B
Weighted average by Cap. -0.28%-0.04%+4.31%+10.50%

Financials

2026 *2027 *
Net sales 36.22M 26.08M 22.38M 21.01M 19.19M 2.49B 36.39M 249M 96.36M 1.25B 97.92M 95.8M 4.16B 59.46M 42.82M 36.75M 34.49M 31.5M 4.08B 59.74M 408M 158M 2.06B 161M 157M 6.82B
Net income -44.08M -31.74M -27.24M -25.57M -23.36M -3.03B -44.29M -303M -117M -1.53B -119M -117M -5.06B -31.27M -22.52M -19.33M -18.14M -16.57M -2.15B -31.42M -215M -83.19M -1.08B -84.54M -82.7M -3.59B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
26/08/26 CA$9.900 +5.10% 54,179
25/08/26 CA$9.420 -0.63% 14,115
24/08/26 CA$9.480 +1.72% 5,603
21/08/26 CA$9.320 +2.42% 1,517
20/08/26 CA$9.100 -6.67% 12,241
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.900
Average target price
-

Quarterly revenue - Rate of surprise